Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Umpqua Bank

Umpqua Bank raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 6.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,689 shares of the medical instruments supplier’s stock after buying an additional 167 shares during the quarter. Umpqua Bank’s holdings in Becton, Dickinson and Company were worth $628,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Livelsberger Financial Advisory purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $27,000. OLD Point Trust & Financial Services N A acquired a new position in Becton, Dickinson and Company during the fourth quarter worth $29,000. Scarborough Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter worth $32,000. Rise Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $38,000. Finally, ICA Group Wealth Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $42,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BDX. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price for the company. Citigroup dropped their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Finally, Evercore ISI reduced their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average price target of $279.50.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $232.67 on Friday. The firm has a market capitalization of $67.24 billion, a price-to-earnings ratio of 51.25, a PEG ratio of 1.98 and a beta of 0.42. The firm’s fifty day simple moving average is $234.06 and its 200-day simple moving average is $235.93. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $269.52. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm earned $2.96 earnings per share. Equities analysts forecast that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Insider Activity at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.31% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.